Breast cancer

March 31, 2021

Molecular signature panel for DCIS predicts risk of local recurrence and benefit of radiotherapy after breast conservative surgery.

Radiotherapy after breast-conserving surgery for the treatment of ductal carcinoma in situ (DCIS) reduces the risk of ipsilateral breast events without changing survival   Between March 18th and 19th, SSO 2021 (International Conference […]
July 15, 2020

Combination of abemaciclib and adjuvant hormone therapy increases invasive disease-free survival in high-risk early breast cancer RH + HER2-

New therapeutic option for patients with high-risk HR-positive, HER2-negative breast cancer Abemaciclib in combination with standard adjuvant endocrine therapy (ET) achieved its primary objective in the […]
May 14, 2020

FDA approves Tucatinib in combination with trastuzumab plus capecitabine for HER2-positive advanced breast cancer

Approval is based on exclusive clinical trial that included patients with active brain metastases On April 17, 2020, the U.S. FDA (US Food and Drug Administration) […]
May 13, 2020

FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple-negative breast cancer

Fast Track is based on the response rate and duration of the response and reinforces the premise that the Trop-2 antigen is an important target to […]
May 8, 2020

Pre-existing mutations in ESR1 in early-stage breast cancer predict worse survival and hormone therapy failure

This pre-existing resistance mutation was related to a worse outcome in terms of overall survival and recurrence-free survival During the virtual session of the annual conference […]
May 4, 2020

Overall survival data released from Phase III EMBRACA Trial

Tazolaparib has shown no OS benefit in patients with advanced/metastatic negative HER2 breast cancer and germline BRCA1 / 2 mutations (gBRCAm) The Overall Survival (OS) results […]
March 31, 2020
Breast cancer: new subcutaneous formulation of pertuzumab and trastuzumab

Breast cancer: new subcutaneous formulation of pertuzumab and trastuzumab

According to the manufacturer’s recent statement, the combination of durvalumab and tremelimumab did not lead to an increase in overall survival (OS) in patients undergoing treatment […]
March 25, 2020
Association of fulvestrant and capivasertib increases progression free survival in patients with breast cancer

Association of fulvestrant and capivasertib increases progression free survival in patients with breast cancer

Through a phase II study recently published in the journal Lancet Oncology, an AKT inhibitor for the first time demonstrates effectiveness in the metastatic breast cancer […]
February 27, 2020

FDA approves therapy that benefits highly pretreated breast cancer patients

On February 25, The US Food and Drug Administration (FDA) approved neratinib (Nerlynx®) in combination with capecitabine (Xeloda®) for the treatment of adult patients with advanced […]